Ossiam Sells 22,234 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Ossiam cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 59.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,160 shares of the biopharmaceutical company’s stock after selling 22,234 shares during the period. Ossiam’s holdings in Regeneron Pharmaceuticals were worth $7,959,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Activest Wealth Management lifted its position in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 21 shares during the last quarter. Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at $27,000. Colonial Trust Advisors bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $32,000. SouthState Corp boosted its stake in shares of Regeneron Pharmaceuticals by 550.0% during the 1st quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 44 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $31,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Down 2.1%

Shares of REGN stock opened at $703.26 on Tuesday. The stock’s fifty day moving average price is $653.54 and its 200 day moving average price is $588.99. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $800.99. The company has a market cap of $73.91 billion, a price-to-earnings ratio of 16.84, a price-to-earnings-growth ratio of 2.06 and a beta of 0.37. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm’s revenue was up .9% compared to the same quarter last year. During the same period last year, the business posted $12.46 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Truist Financial initiated coverage on Regeneron Pharmaceuticals in a report on Monday, November 24th. They set a “buy” rating and a $798.00 price objective for the company. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, November 17th. Finally, UBS Group upped their price objective on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $777.36.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.